Q2 STOCKS TO BUY

25% Drop Sets Off Sarepta Therapeutics Inc (SRPT) Options Trading

Eteplirsen's prospects at the FDA look bleak -- and Sarepta Therapeutics Inc (SRPT) shares are paying the price

Jun 2, 2016 at 2:05 PM
facebook X logo linkedin


Sarepta Therapeutics Inc (NASDAQ:SRPT) has shed roughly one-quarter of its value today at $16.01, and landed on the short-sale restricted list. Taking a toll on the stock are rumblings the U.S. Food and Drug Administration (FDA) could pressure the drugmaker to provide its Duchenne muscular dystrophy (DMD) treatment, eteplirsen, to patients at cost -- rather than granting it accelerated approval. Amid the news, SRPT options are flying off the shelves.

At last check, over 68,000 options are on the tape -- tripling the expected intraday amount. The most active strike is the June 30 call, where it's possible traders may be purchasing new positions to bet on a big bounce by front-month expiration, at the close on Friday, June 17. Clearer-cut buy-to-open (BTO) activity is detected at SRPT's weekly 6/10 25-strike call, as option bulls expect a rally past the quarter-century mark by next Friday's close, when the weekly series expires.

Longer term, though, put buying has been accelerated. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), SRPT's 50-day put/call volume ratio of 0.57 registers just 4 percentage points from a 12-month peak. Likewise, short-term open interest levels are tilted in a relatively put-skewed direction. This, based on the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.56, which ranks in the high 86th annual percentile.

Outside of the options pits, doubters abound. Short interest surged over 23% during the last two reporting periods, and now accounts for over three-fifths of the stock's float. As such, some of today's BTO activity at the out-of-the-money calls could be a result of shorts hedging their bearish bets against any upside risk. Elsewhere, 10 of 13 analysts rate SRPT a "hold" or worse.

Today's FDA rumors have certainly been a boon to bears. In fact, in a research note, Jefferies described eteplirsen's chances of receiving regulatory approval as "slim." If that becomes official, it may serve as another setback for SRPT stock.

Suffice it to say, Sarepta Therapeutics Inc (NASDAQ:SRPT) has gotten bloodied up on the charts -- and not just today. Since the start of 2016, the shares have surrendered over 58% of their value, and are poised to close below their 80-day moving average for the first time since late April.

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 
 

“Buy This Stock Now!” - Expert Who Called 11x On TSLA

He called a rare 11x on Tesla…

But now, thanks to Elon & Trump’s new alliance…

He says there’s a new opportunity that could be 1,000x BIGGER than Tesla – and it could completely revolutionize a $23 Trillion market.

It’s trading for less than $5 per share right now…

But it won’t be under the radar for long.

Discover The 1,000x Bigger Elon Opportunity Here

GRAND SLAM COUNTDOWN

 
 

Featured Articles from Trusted Partners:

👀Learn How Dividends Create Passive Income for Life
Receive $200 Off Motley Fool Epic. The Motley Fool Epic $299 discounted offer is based on $499/year list price. Introductory promotion for new members only. Take control of your money and your portfolio with Motley Fool Epic.

💵New Income System Could Pay You $4,243 Monthly
You could collect an average of $4,243 per month starting as early as next week with a new payout system for income investors. New registrations are being accepted for investors who want to be in a position to start with their first payout next week.

🚀Easy 92% Crypto Dividends (No Coins Required)
COIN stock doesn't pay a dividend... But there's actually a new way to collect a massive dividend that's indirectly based on the stock and offers a terrific monthly income (currently yielding nearly 92% on a forward basis).

🤝Free Advisor Match with Wiseradvisor.com
Don't leave your retirement to chance! Get matched with a trusted financial expert for FREE and make the most of your tax refund. Get started now.

⚠️Dennis Quaid's #1 Warning for Americans
Here's the thing: life doesn't come with guarantees. The economy shifts, markets stumble, and years of hard work could slip through your fingers like sand. But it doesn't have to be that way for you. So request a free copy of this Gold & Silver Guide that will arrive right to your doorstep when you act now.

 

 
 

Follow us on X, Follow us on Twitter